Compare RDW & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | ANIP |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | 1410 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | N/A | 1999 |
| Metric | RDW | ANIP |
|---|---|---|
| Price | $9.05 | $77.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.71 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 22.4M | 297.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $41.68 | $21.01 |
| Revenue Next Year | $20.25 | $17.59 |
| P/E Ratio | ★ N/A | $60.72 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $4.87 | $62.61 |
| 52 Week High | $26.64 | $99.50 |
| Indicator | RDW | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 36.77 |
| Support Level | $8.39 | $77.16 |
| Resistance Level | $10.43 | $77.47 |
| Average True Range (ATR) | 0.75 | 2.51 |
| MACD | -0.07 | -0.80 |
| Stochastic Oscillator | 20.06 | 4.32 |
Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.